Literature DB >> 10081911

Identification of an activin-follistatin growth modulatory system in the human prostate: secretion and biological activity in primary cultures of prostatic epithelial cells.

Q Wang1, S Tabatabaei, B Planz, C W Lin, P M Sluss.   

Abstract

PURPOSE: To determine if the activin/follistatin system is present in human prostate tissue and primary cultures of prostatic epithelium and if these growth factors play a role in the control of epithelial cell growth.
MATERIALS AND METHODS: Cells derived directly from human prostates were studied to determine: a) if they secrete activin and follistatin, and b) if they are growth inhibited by activin. Primary cell cultures were established from tissues removed from 13 unselected prostate carcinoma patients in order to examine the secretion of activin and follistatin and test the effects of these proteins on cell proliferation.
RESULTS: Both primary explant cells and epithelial cells isolated and sub-cultured from explant cultures secreted activin A and follistatin. Treatment of cultured cells with recombinant human activin A resulted in a dose-dependent inhibition of thymidine incorporation, with an IC50 of 0.22 nM. Recombinant follistatin neutralized the inhibitory effects of activin A on cell proliferation whilst adding follistatin alone enhanced thymidine incorporation, suggesting a similar neutralizing effect on the endogenous activin produced by these cells.
CONCLUSION: These results demonstrate that cells derived from human prostate tissue secrete activin and follistatin and, as observed in human prostate cancer cell lines, activin inhibited the growth of prostatic epithelial cells. Also consistent with our earlier studies of prostate cancer cell lines, the biological activity of activin was neutralized by follistatin. These observations support the hypothesis that the activin/follistatin system plays an important role in the local regulation of human prostate cell growth.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10081911

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

Review 1.  Physical activity and its mechanistic effects on prostate cancer.

Authors:  A Wekesa; M Harrison; R W Watson
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-03-24       Impact factor: 5.554

2.  Serum follistatin in patients with prostate cancer metastatic to the bone.

Authors:  Francesca Maria Tumminello; Giuseppe Badalamenti; Fabio Fulfaro; Lorena Incorvaia; Marilena Crescimanno; Carla Flandina; Maria Vittoria Sepporta; Gaetano Leto
Journal:  Clin Exp Metastasis       Date:  2010-07-11       Impact factor: 5.150

Review 3.  Follistatin as potential therapeutic target in prostate cancer.

Authors:  Maria Vittoria Sepporta; Francesca Maria Tumminello; Carla Flandina; Marilena Crescimanno; Marco Giammanco; Maurizio La Guardia; Danila di Majo; Gaetano Leto
Journal:  Target Oncol       Date:  2013-03-01       Impact factor: 4.493

4.  Peroxisome proliferator-activated receptor gamma down-regulates follistatin in intestinal epithelial cells through SP1.

Authors:  Brian M Necela; Weidong Su; E Aubrey Thompson
Journal:  J Biol Chem       Date:  2008-09-03       Impact factor: 5.157

5.  Effect of keratinocyte growth factor and activin on cell growth in the human prostatic cancer cell line LNCaP.

Authors:  Bernhard Planz; Horia Oltean; Thomas Deix; Sandra D Kirley; Qi Fa Wang; W S McDougal; Michael Marberger
Journal:  World J Urol       Date:  2004-02-27       Impact factor: 4.226

6.  Interaction of testosterone with inhibin alpha and betaA subunits to regulate prostate gland growth.

Authors:  Falah Shidaifat; Ibrahim Al-Zuhair; Zuhair Bani-Ismail
Journal:  Endocrine       Date:  2007-02       Impact factor: 3.633

Review 7.  Intertwining of Activin A and TGFβ Signaling: Dual Roles in Cancer Progression and Cancer Cell Invasion.

Authors:  Holli A Loomans; Claudia D Andl
Journal:  Cancers (Basel)       Date:  2014-12-30       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.